ISAKOS: 2019 Congress in Cancun, Mexico

2019 ISAKOS Biennial Congress ePoster #310


Clinical Results of a Novel 3D Fresh Cartilage Matrix for Focal Articular Cartilage Defects

Vishal M. Mehta, MD, Naperville, IL UNITED STATES
Cassie Mandala, PAC, Geneva, IL UNITED STATES
Ryan J. Shriver, BS, Geneva, IL UNITED STATES

Fox Valley Orthopaedics, Geneva, IL, UNITED STATES

FDA Status Cleared


This paper demonstrates the three year clinical results of a fresh cartilage matrix in the treatment of focal articular cartilage injuries.



Despite improvements in treatment, articular cartilage lesions continue to be a major source of pain and disability. A recently developed fresh, cartilage allograft (ProChondrix, Allosource, Centennial, CO) has become available for treatment of articular cartilage lesions. This graft contains extracellular matrix, native growth factors and viable chondrocytes. While it has demonstrated promising results in laboratory and equine studies, its efficacy in human clinical use remains unknown. The purpose of this study is to evaluate the three year follow-up results of a novel 3D fresh cartilage matrix on isolated articular cartilage defects.


17 patients with isolated, symptomatic articular cartilage surface lesions were treated with microfracture followed by placement of a ProChondrix graft. Demographic and intra-operative data was recorded as well as pre- and post-operative International Knee Documentation Committee (IKDC), Short Form-36 (SF-36), Knee Injury and Osteoarthritis Outcome Score (KOOS), Visual Analogue Scale (VAS) and Tegner scores. Pre- and post-operative data was compared at 6, 12, 24, and 36 months post-operatively. Failures requiring reoperation were also recorded.


At a mean follow-up of 2.5 years (6-43 months), VAS decreased from 6.55 to 2.55 (p=.02) and subjective IKDC scores increased from 37.61 to 59.65 (p=.02). Statistically significant increases were also seen in KOOS Function-Sports and Recreational Activities (+26.04, p=.04) and KOOS QOL (+18.76, p=.007) as well as in SF-36 Physical Functioning (+25.20, p=.04), Energy/Fatigue (+16.50, p=.02), Social Functioning (+11.79, p=.04), and Bodily Pain (+25.18, p=.04). There were two failures requiring reoperation: one conversion to a PFA, and one graft dislodging.


Treatment of articular cartilage lesions with ProChondrix have demonstrated sustained positive results out to 3 years in this case series. 2 failures required reoperation in this series